Individualized vaccines for cancer
AssigneesTRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech SE
InventorsUgur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Jan Diekmann
Life of this patent
Estimating the term…
Abstract
The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of. (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
Claims30
A method comprising:
- (a) administering to a subject having a tumor of a particular cancer type a first vaccine comprising a set of pre-manufactured vaccine products, wherein each pre-manufactured vaccine product comprises one or more nucleic acids encoding one or more distinct shared tumor antigens, wherein the shared tumor antigens are each shared by at least 80% of subjects having the cancer type;
- and
- (b) administering to the subject a second vaccine comprising one or more nucleic acids encoding a plurality of neo-epitopes, wherein each neo-epitope comprises at least one cancer-specific somatic mutation that is determined to be present in a sample comprising cancer cells from the subject and not present in a sample comprising non-cancer cells from the same subject.
Dependencies are inferred from the claim text.